A signal before symptoms The research concerns inflammatory bowel disease, or IBD, including its two main forms, Crohn’s disease and ulcerative colitis. The central finding is that people who later developed these conditions carried different blood-antibody patterns from those seen in a comparison group. Those patterns were detectable as much as 10 years before an IBD diagnosis, according to the two supplied reports. The result points to a period in which measurable immune changes may precede the point at which the disease is diagnosed.
The timing matters because the source material describes Crohn’s disease and ulcerative colitis as conditions that are typically treated after symptoms appear. The Guardian reports that, by that stage, damage to the gut may already have occurred. Against that background, an antibody signal appearing years earlier could give doctors a way to investigate risk before a diagnosis is made. That possibility is the basis for the study’s significance; the evidence does not show that every person with one of the patterns will go on to develop IBD.
What the study examined According to The Guardian, the researchers examined 2,000 blood samples from 500 people. The group included 200 people who later developed Crohn’s disease, 200 who later developed ulcerative colitis and 100 who developed neither condition. The samples were screened for antibodies produced in response to a very large range of protein fragments from bacteria, viruses, food and the body’s own tissues. This design allowed the researchers to compare immune patterns before diagnosis across people who later followed different clinical paths.
The Guardian attributes the work to Dr Arno Bourgonje and colleagues linked to the University Medical Centre Groningen, the Icahn School of Medicine at Mount Sinai and the Medical University of Vienna. The supplied report describes the samples as having been taken from US military personnel. It also says that the study’s findings were published in the journal Gut. These details provide the reported research setting, but the supplied evidence does not identify a precise diagnostic score, a proposed screening schedule or the performance of a test that doctors could order routinely.
Different diseases, different immune patterns The reported signals were not identical for the two forms of IBD. In people who later developed Crohn’s disease, antibodies against Epstein-Barr virus were more common, and The Guardian reports that the difference could already be seen a decade before diagnosis. The same report says the signal was strongest among people who later developed more severe, complicated disease, including disease that can narrow the bowel or create abnormal channels. That observation may offer a route to studying future disease course, but it does not establish that the antibody pattern itself causes, determines or reliably predicts severity.
People who later developed ulcerative colitis showed another pattern, according to The Guardian. It included antibodies directed against one of the body’s own proteins, rather than reproducing the signal reported in the future Crohn’s disease group. The distinction is important because it suggests that immune changes before diagnosis may not be a single general marker for all IBD. Instead, the findings could help researchers examine whether Crohn’s disease and ulcerative colitis begin through partly different biological processes, although the supplied evidence does not establish the mechanism behind either pattern.
From research finding to possible application The findings were presented at the United European Gastroenterology meeting in Barcelona, a meeting Medical Xpress identifies as UEG Week 2026. Both supplied sources describe the work as opening a possibility for earlier detection of people at elevated risk. The Guardian reports that earlier treatment, and eventually prevention, are hopes attached to this kind of research. Those are future applications rather than outcomes demonstrated by the study: the reports do not show that acting on the antibody patterns improves health, delays disease or prevents IBD.
The potential value would lie in shifting attention to the period before a patient receives an IBD diagnosis. The source material describes the immune system as leaving warning signals long before symptoms become apparent, and it presents the research as an effort to identify people at risk before damage begins. But the evidence supplied here does not establish how the patterns would be used alongside symptoms, imaging, other laboratory findings or clinical examination. Nor does it say how many people without IBD might show similar antibodies.
What remains unproven The Guardian reports that the findings need to be confirmed in other groups of people. It also cautions that the results show an association rather than proving that the infections linked to the antibody findings cause IBD. That limitation is especially relevant to the Crohn’s disease signal involving Epstein-Barr virus: the presence of more antibodies does not, on the supplied evidence, demonstrate a causal role for the virus. The research therefore identifies a relationship that warrants further study, not an explanation of why the disease develops.
The same caution applies to the idea of prediction. According to The Guardian, the antibody techniques remain a research tool and are not yet ready for clinical use. The available evidence does not provide predictive accuracy, a threshold for a positive result or proof that the approach works outside the reported study group. It consequently cannot support a claim that doctors can currently use the patterns to tell an individual that they will develop Crohn’s disease or ulcerative colitis.
An independent view included in The Guardian report was similarly measured. James Lindsay, a professor of gastroenterology at Barts Health who was not involved in the research, described the study as providing important insights into Crohn’s disease and ulcerative colitis and potentially adding tools for identifying people at risk. He also cautioned that the techniques were still very much a research tool rather than something ready for the clinic. Marianne Radcliffe of Crohn’s & Colitis UK said the work was an important step toward understanding changes that may occur years before symptoms appear.
A possible earlier-warning model, not a clinical test The reports place the study within a broader effort to find signs of IBD before symptoms and gut damage become evident. They suggest that, if the patterns are confirmed and translated into a reliable method, clinicians might eventually identify some people at elevated risk earlier than they can now. The supplied evidence does not establish that this stage has been reached. For now, the firm findings are the existence of distinct antibody patterns, their detection up to 10 years before diagnosis and the differences reported between future Crohn’s disease and ulcerative colitis groups.
The next evidentiary step described by the reporting is confirmation in other groups, followed by work to determine whether the signals can support decisions that improve outcomes. Until that happens, the study is best understood as an early warning of biological change rather than a diagnosis. Its importance lies in showing that the immune system may carry detectable information years before inflammatory bowel disease is formally identified, while its clinical implications remain to be established.